GNI Group Ltd. (2160.T)
JPY 3460.0
(2.37%)
JPY 3460.0
(2.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.34 Billion JPY | 86.87% |
| 2022 | 14.09 Billion JPY | 27.79% |
| 2021 | 11.03 Billion JPY | 5.56% |
| 2020 | 10.45 Billion JPY | 39.12% |
| 2019 | 7.51 Billion JPY | 107.95% |
| 2018 | 3.61 Billion JPY | 50.66% |
| 2017 | 2.39 Billion JPY | 86.47% |
| 2016 | 1.28 Billion JPY | 2.23% |
| 2015 | 1.25 Billion JPY | 28.9% |
| 2014 | 975.71 Million JPY | 25.26% |
| 2013 | 778.97 Million JPY | 44.36% |
| 2012 | 539.62 Million JPY | 33.65% |
| 2011 | 403.77 Million JPY | 779.23% |
| 2010 | 45.92 Million JPY | 0.0% |
| 2008 | 114.85 Million JPY | -43.41% |
| 2007 | 202.96 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.84 Billion JPY | 5.71% |
| 2024 Q2 | 29.42 Billion JPY | 5.69% |
| 2023 Q1 | 14.28 Billion JPY | 1.34% |
| 2023 Q4 | 26.34 Billion JPY | 20.38% |
| 2023 Q3 | 21.88 Billion JPY | 8.04% |
| 2023 Q2 | 20.25 Billion JPY | 41.78% |
| 2023 FY | 26.34 Billion JPY | 86.87% |
| 2022 Q3 | 14.44 Billion JPY | 6.94% |
| 2022 Q4 | 14.09 Billion JPY | -2.39% |
| 2022 FY | 14.09 Billion JPY | 27.79% |
| 2022 Q1 | 12.11 Billion JPY | 9.85% |
| 2022 Q2 | 13.5 Billion JPY | 11.45% |
| 2021 Q1 | 9.84 Billion JPY | -5.74% |
| 2021 Q3 | 10.35 Billion JPY | 4.54% |
| 2021 Q4 | 11.03 Billion JPY | 6.48% |
| 2021 FY | 11.03 Billion JPY | 5.56% |
| 2021 Q2 | 9.9 Billion JPY | 0.61% |
| 2020 Q3 | 8.24 Billion JPY | 3.03% |
| 2020 Q2 | 8 Billion JPY | -2.02% |
| 2020 FY | 10.45 Billion JPY | 39.12% |
| 2020 Q4 | 10.45 Billion JPY | 26.77% |
| 2020 Q1 | 8.16 Billion JPY | 8.71% |
| 2019 Q1 | 7.74 Billion JPY | 114.42% |
| 2019 FY | 7.51 Billion JPY | 107.95% |
| 2019 Q4 | 7.51 Billion JPY | 6.35% |
| 2019 Q3 | 7.06 Billion JPY | -0.24% |
| 2019 Q2 | 7.07 Billion JPY | -8.59% |
| 2018 Q4 | 3.61 Billion JPY | 50.61% |
| 2018 Q2 | 2.41 Billion JPY | -0.85% |
| 2018 FY | 3.61 Billion JPY | 50.66% |
| 2018 Q3 | 2.39 Billion JPY | -0.82% |
| 2018 Q1 | 2.43 Billion JPY | 1.73% |
| 2017 Q1 | 1.62 Billion JPY | 26.13% |
| 2017 Q4 | 2.39 Billion JPY | 28.98% |
| 2017 FY | 2.39 Billion JPY | 86.47% |
| 2017 Q3 | 1.85 Billion JPY | -15.61% |
| 2017 Q2 | 2.2 Billion JPY | 35.82% |
| 2016 Q2 | 1.12 Billion JPY | -9.22% |
| 2016 Q4 | 1.28 Billion JPY | 15.05% |
| 2016 Q3 | 1.11 Billion JPY | -0.63% |
| 2016 FY | 1.28 Billion JPY | 2.23% |
| 2016 Q1 | 1.23 Billion JPY | -1.5% |
| 2015 FY | 1.25 Billion JPY | 28.9% |
| 2015 Q3 | 1.16 Billion JPY | -5.41% |
| 2015 Q2 | 1.22 Billion JPY | 1.32% |
| 2015 Q1 | 1.21 Billion JPY | 24.14% |
| 2015 Q4 | 1.25 Billion JPY | 8.34% |
| 2014 FY | 975.71 Million JPY | 25.26% |
| 2014 Q2 | 690.08 Million JPY | -10.63% |
| 2014 Q4 | 975.71 Million JPY | -6.88% |
| 2014 Q3 | 1.04 Billion JPY | 51.83% |
| 2014 Q1 | 772.19 Million JPY | -0.87% |
| 2013 Q2 | 870.27 Million JPY | 57.0% |
| 2013 Q3 | 1.02 Billion JPY | 17.68% |
| 2013 FY | 778.97 Million JPY | 44.36% |
| 2013 Q4 | 778.97 Million JPY | -23.94% |
| 2013 Q1 | 554.3 Million JPY | 2.72% |
| 2012 FY | 539.62 Million JPY | 33.65% |
| 2012 Q1 | 490.12 Million JPY | 21.39% |
| 2012 Q2 | 479.11 Million JPY | -2.25% |
| 2012 Q3 | 460.83 Million JPY | -3.81% |
| 2012 Q4 | 539.62 Million JPY | 17.1% |
| 2011 Q2 | 44.47 Million JPY | 1.0% |
| 2011 Q4 | 403.77 Million JPY | -7.94% |
| 2011 FY | 403.77 Million JPY | 779.23% |
| 2011 Q3 | 438.61 Million JPY | 886.12% |
| 2011 Q1 | 44.04 Million JPY | -4.1% |
| 2010 Q1 | 41.65 Million JPY | 0.0% |
| 2010 FY | 45.92 Million JPY | 0.0% |
| 2010 Q3 | 28.68 Million JPY | -14.81% |
| 2010 Q2 | 33.67 Million JPY | -19.16% |
| 2010 Q4 | 45.92 Million JPY | 60.11% |
| 2009 Q3 | 80 Million JPY | -20.02% |
| 2009 Q2 | 100.02 Million JPY | -12.92% |
| 2009 Q1 | 114.85 Million JPY | -25.99% |
| 2008 FY | 114.85 Million JPY | -43.41% |
| 2008 Q4 | 155.18 Million JPY | 0.0% |
| 2007 FY | 202.96 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -711.277% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -41441.04% |
| Linical Co., Ltd. | 10.3 Billion JPY | -155.622% |
| Trans Genic Inc. | 3.81 Billion JPY | -590.92% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -4363.133% |
| Soiken Holdings Inc. | 697.02 Million JPY | -3679.156% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -772.022% |
| AnGes, Inc. | 2.78 Billion JPY | -844.357% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -5028.744% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 70.857% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -7356.482% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -1496.566% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -5476.651% |
| CanBas Co., Ltd. | 91.98 Million JPY | -28535.897% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -2308.691% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -3152.731% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -4336.62% |
| Kidswell Bio Corporation | 4.25 Billion JPY | -519.208% |
| PeptiDream Inc. | 29.11 Billion JPY | 9.524% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -4549.883% |
| Ribomic Inc. | 155.8 Million JPY | -16806.333% |
| SanBio Company Limited | 2.25 Billion JPY | -1068.197% |
| Healios K.K. | 11.28 Billion JPY | -133.401% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -10383.422% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -7038.642% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -10807.626% |
| StemRIM | 187 Million JPY | -13986.411% |
| CellSource Co., Ltd. | 677.73 Million JPY | -3786.686% |
| FunPep Company Limited | 189.32 Million JPY | -13813.497% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -4312.659% |
| Stella Pharma Corporation | 1.44 Billion JPY | -1724.703% |
| TMS Co., Ltd. | 97.68 Million JPY | -26864.744% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -28690.51% |
| Cuorips Inc. | 200.96 Million JPY | -13007.811% |
| K Pharma,Inc. | 209.13 Million JPY | -12495.555% |
| Takara Bio Inc. | 11.42 Billion JPY | -130.662% |
| ReproCELL Incorporated | 741.03 Million JPY | -3454.717% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -2770.352% |
| StemCell Institute Inc. | 3.85 Billion JPY | -584.115% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -2799.68% |
| CellSeed Inc. | 301.04 Million JPY | -8649.992% |